Mariner LLC Raises Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mariner LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 13,666 shares of the biopharmaceutical company’s stock after purchasing an additional 1,947 shares during the quarter. Mariner LLC’s holdings in Alnylam Pharmaceuticals were worth $3,216,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock worth $2,996,296,000 after buying an additional 98,303 shares during the period. Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $1,045,822,000. Norges Bank acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $577,941,000. Geode Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 2,206,800 shares of the biopharmaceutical company’s stock valued at $518,367,000 after buying an additional 59,597 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.7% during the 4th quarter. American Century Companies Inc. now owns 1,604,024 shares of the biopharmaceutical company’s stock worth $377,443,000 after buying an additional 11,291 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ALNY shares. Wells Fargo & Company raised their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a report on Friday, March 21st. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. Royal Bank of Canada boosted their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research note on Friday, March 21st. Finally, Bank of America raised their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $315.58.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the sale, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. The trade was a 10.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the transaction, the chief financial officer now owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. This trade represents a 2.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Trading Down 0.8 %

Shares of ALNY opened at $232.75 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The stock’s 50-day moving average is $248.47 and its two-hundred day moving average is $256.64. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market cap of $30.28 billion, a PE ratio of -107.26 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.